On Monday, Artiva Biotherapeutics Inc (NASDAQ: ARTV) opened lower -6.84% from the last session, before settling in for the closing price of $5.41. Price fluctuations for ARTV have ranged from $1.47 to $15.49 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -64.01%. Company’s average yearly earnings per share was noted 40.53% at the time writing. With a float of $12.46 million, this company’s outstanding shares have now reached $24.39 million.
Artiva Biotherapeutics Inc (ARTV) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Artiva Biotherapeutics Inc is 48.97%, while institutional ownership is 53.66%. The most recent insider transaction that took place on Oct 17 ’25, was worth 153,000. In this transaction President and CEO of this company sold 25,500 shares at a rate of $6.00, taking the stock ownership to the 356,721 shares. Before that another transaction happened on Oct 17 ’25, when Company’s Director proposed sale 25,500 for $2.77, making the entire transaction worth $70,635.
Artiva Biotherapeutics Inc (ARTV) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.87 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.63) by -0.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.79% during the next five years compared to -64.01% drop over the previous five years of trading.
Artiva Biotherapeutics Inc (NASDAQ: ARTV) Trading Performance Indicators
Check out the current performance indicators for Artiva Biotherapeutics Inc (ARTV). In the past quarter, the stock posted a quick ratio of 13.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.09, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Artiva Biotherapeutics Inc (ARTV)
Looking closely at Artiva Biotherapeutics Inc (NASDAQ: ARTV), its last 5-days average volume was 0.76 million, which is a drop from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 51.18%.
During the past 100 days, Artiva Biotherapeutics Inc’s (ARTV) raw stochastic average was set at 60.61%, which indicates a significant increase from 50.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.62 in the past 14 days, which was higher than the 0.30 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.17, while its 200-day Moving Average is $3.22. However, in the short run, Artiva Biotherapeutics Inc’s stock first resistance to watch stands at $5.52. Second resistance stands at $5.99. The third major resistance level sits at $6.38. If the price goes on to break the first support level at $4.66, it is likely to go to the next support level at $4.27. Now, if the price goes above the second support level, the third support stands at $3.80.
Artiva Biotherapeutics Inc (NASDAQ: ARTV) Key Stats
There are currently 24,426K shares outstanding in the company with a market cap of 123.11 million. Presently, the company’s annual sales total 250 K according to its annual income of -65,370 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,250 K.
